General
Preferred name
PREXASERTIB
Synonyms
Prexasertib (Mesylate Hydrate) ()
LY2606368 Mesylate Hydrate ()
LY2940930 ()
Prexasertib 2HCl ()
LY2606368 (dihydrochloride) ()
LY2606368 2HCl ()
LY2606368 ()
LY2606368 (dihydrochloride)Prexasertib HCl ()
LY-2606368 ()
Prexasertib (dihydrochloride) ()
Prexasertib (dimesylate) ()
LY2606368 (dimesylate) ()
ACR 368 ()
LY2606368 dihydrochloride ()
Prexasertib HCl (LY2606368) ()
Prexasertib (LY2606368) ()
Prexasertib dihydrochloride ()
LY2606368 ()
P&D ID
PD057524
CAS
1234015-52-1
1234015-54-3
1234015-58-7
Tags
available
drug candidate
Drug indication
Head and neck cancer
Small-cell lung cancer
Squamous cell anal carcinoma
Ovarian cancer
Neoplasm
Solid tumour/cancer
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Prexasertib (LY2606368), an investigational small molecule checkpoint kinase 1 (CHK1) inhibitor that exhibits anti-tumour activity in preclinical models of pediatric cancer. (GtoPdb)
DESCRIPTION Prexasertib (LY2606368) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib shows potent anti-tumor activity[1][2].
PRICE 154
DESCRIPTION Prexasertib dihydrochloride (LY2606368 dihydrochloride) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dihydrochloride inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dihydrochloride causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dihydrochloride shows potent anti-tumor activity[1][2].
PRICE 132
DESCRIPTION Prexasertib dimesylate (LY2606368 dimesylate) is a selective, ATP-competitive second-generation checkpoint kinase 1 (CHK1) inhibitor with a Ki of 0.9 nM and an IC50 of <1 nM. Prexasertib dimesylate inhibits CHK2 (IC50=8 nM) and RSK1 (IC50=9 nM). Prexasertib dimesylate causes double-stranded DNA breakage and replication catastrophe resulting in apoptosis. Prexasertib dimesylate shows potent anti-tumor activity[1][2].
DESCRIPTION Prexasertib (LY2606368) is an inhibitor of checkpoint kinase 1 (chk1) with potential antineoplastic activity. (TargetMol Bioactive Compound Library)
DESCRIPTION The dihydrochloride salt form of LY2606368 which also known as prexasertib, is an inhibitor of checkpoint kinase 1 and has potential effect in antineoplastic. It is still under Phase II clinical trial against breast cancer and some other sorts of cancers. (BOC Sciences Bioactive Compounds)
DESCRIPTION Prexasertib dihydrochloride (LY2606368) is an ATP-competitive CHK1 inhibitor (Ki: 0.9 nmol/L). in the cell-free assay, its IC50 values are 8 nM and 9 nM for CHK2 and RSK, respectively. (TargetMol Bioactive Compound Library)
Cell lines
10
Organisms
0
Compound Sets
16
AdooQ Bioactive Compound Library
A13684
BOC Sciences Bioactive Compounds
ly2606368-dihydrochloride-cas-1234015-54-3-item-474413
Cayman Chemical Bioactives
21490
ChEMBL Drugs
CHEMBL3544911
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB12008
DrugMAP
DM4XMF7
EU-OPENSCREEN Bioactive Compound Library
EOS100438
Guide to Pharmacology
9549
MedChem Express Bioactive Compound Library
HY-18174
HY-18174A
HY-18174E
Other bioactive compounds
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
prexasertib-ly2606368
ly2606368
TargetMol Bioactive Compound Library
T4310
T4327
External IDs
45
Properties
(calculated by RDKit )
Molecular Weight
365.16
Hydrogen Bond Acceptors
8
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
2.22
TPSA
134.76
Fraction CSP3
0.22
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Checkpoint Kinase (Chk)
Apoptosis
CHK1
CHK2
Ribosomal S6 Kinase (RSK)
CHEK1
Chk
Chk,S6 Kinase
CHEK2
Pathway
Cell Cycle/DNA Damage
Cell Cycle/Checkpoint
MAPK
PI3K/Akt/mTOR signaling
MOA
Chk inhibitor
Solubility
43mg/ml in DMSO
Source data